Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02329717
Recruitment Status : Unknown
Verified September 2016 by Phoenix Biotechnology, Inc.
Recruitment status was:  Active, not recruiting
First Posted : January 1, 2015
Last Update Posted : September 29, 2016
Information provided by (Responsible Party):
Phoenix Biotechnology, Inc

Brief Summary:
This study evaluates the efficacy and safety of PBI-05204, an extract of the leaves of Nerium oleander, in patients with Stage IV metastatic pancreatic cancer. All patients will receive PBI-05204.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: PBI 05204 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Single-arm, Open-label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma
Study Start Date : April 2015
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: PBI 05204
PBI 05204 capsules dosed at 0.2255 mg/kg/day, continuous dosing
Drug: PBI 05204
PBI 05204 daily dosing

Primary Outcome Measures :
  1. overall survival [ Time Frame: 4.5 months ]

Secondary Outcome Measures :
  1. Time to Progression [ Time Frame: up to 1 year ]
  2. Time to Treatment Failure [ Time Frame: up to 1 year ]
  3. Progression free survival [ Time Frame: up to 1 year ]
  4. Overall response rate [ Time Frame: up to 1 year ]
  5. Tumor control rate [ Time Frame: up to 1 year ]
  6. Duration of response [ Time Frame: up to 1 year ]
  7. CA 19-9 response [ Time Frame: up to 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient is male or female aged ≥18 years.
  2. Patient with histologically-confirmed Stage IV malignant metastatic adenocarcinoma of the pancreas; (a) who has relapsed from or is refractory to standard therapy and for whom no therapy exists that would be curative or might provide significant benefit or (b) who are intolerant to or refuse standard chemotherapy and, therefore, for whom experimental therapy is a reasonable option.
  3. Patient has measurable disease, as determined by the Investigator using RECIST, version 1.1, as determined within 28 days before baseline (C1D1).
  4. Patient has an ECOG performance status of 0 (fully active, able to carry out all pre-disease activities without restriction) or 1 (unable to perform physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), as assessed on C1D1, before the first dose of PBI 05204.
  5. Patient has a predicted life-expectancy of ≥3 months.
  6. Patient has adequate bone marrow function defined as:

    • Absolute neutrophil count (ANC) (neutrophil and bands) ≥1.5 x 10 ^9/L
    • Platelet count ≥100 x10^9/L
    • Hemoglobin ≥9.0 g/dL
  7. Patient has adequate hepatic function defined as:

    • Total bilirubin within normal limits (WNL) for the institution, unless the bilirubin abnormality is considered due to Gilbert's syndrome.
    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.0 x the institutional upper limit of normal (ULN), or, in patients with known liver metastases, ≤5.0 x the institutional ULN.
    • Serum albumin ≥3.0 g/dL.
  8. Patient has adequate renal function defined as:

    Serum creatinine ≤1.5 the institutional ULN

  9. Patient has serum potassium and magnesium levels WNL for the institution and total serum calcium or ionized calcium levels ≥ the lower limit of normal (LLN). Patients with low potassium, calcium, and/or magnesium levels may receive supplementation to meet the protocol entry criteria. (Calcium supplementation is prohibited after starting PBI-05204; see Appendix 2.)
  10. Patient provides signed and dated informed consent prior to initiation of any study procedures.
  11. Patient and his/her partner agree to use adequate contraception after providing written informed consent through 3 months after the last dose of PBI 05204, as follows:

    • For women: Negative pregnancy test during screening (Day 3 to Day 1) before C1D1 and compliant with a medically-approved contraceptive regimen during and for 3 months after the treatment period or documented to be surgically sterile (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or postmenopausal (defined as amenorrhea for ≥12 consecutive months; or receiving hormone replacement therapy [HRT] with documented serum follicle stimulating hormone [FSH] level >35 mIU/mL).
    • For men: Compliant with a medically-approved contraceptive regimen during and for 3 months after the treatment period or documented to be surgically sterile. Men whose sexual partners are of child-bearing potential must agree to use a medically-approved contraceptive regimen during the study and for 3 months after the treatment period.
  12. Patient is capable of swallowing study drug capsules whole.
  13. Patient is willing and able to participate in the study and comply with all study requirements.

Exclusion Criteria:

  1. Patient has uncontrolled or significant cardiovascular disease, including:

    • Myocardial infarction within 6 months before C1D1.
    • Uncontrolled angina within 3 months before C1D1.
    • Congestive heart failure, defined as New York Heart Association (NYHA) Class II, within 3 months before C1D1 (see Appendix 1).
    • Diagnosed or suspected congenital long QT syndrome.
    • Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White [WPW] syndrome, or torsade de pointes), or prolonged QTc interval on pre-entry ECG (>450 msec). If the automated reading is prolonged (i.e., >450 msec), the ECG should be manually over-read.
    • Any history of second- or third-degree heart block. (Patients with pacemakers may be eligible.)
    • Heart rate <50 bpm during screening.
    • Uncontrolled hypertension (blood pressure >160 mmHg systolic and >100 mmHg diastolic).
  2. Patient requires the use of concomitant medications that are contraindicated with cardiac glycosides and/or are known to prolong the QT/QTc interval during study participation (see Appendix 2).
  3. Patient has evidence of uncontrolled malabsorptive diarrhea that would prevent adequate absorption of PBI 05204.
  4. Patient has dementia or altered mental status that would prohibit the understanding or rendering of informed consent.
  5. Patient has uncontrolled or severe intercurrent medical condition (including uncontrolled brain metastases). Patients with stable brain metastases either treated or being treated with a stable dose of steroids/anticonvulsants are allowed provided there is no dose change within 4 weeks before the first dose of PBI 05204, and no anticipated dose change during study participation.
  6. Patient underwent major surgery within 4 weeks before the first dose of PBI 05204 or received cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy, biologic or immunotherapy, etc.) or an investigational drug or device within 4 weeks (6 weeks for mitomycin C, nitrosoureas, and liposomal doxorubicin) or 5 half-lives of that agent (whichever is shorter) before the first dose of PBI 05204. (For agents in which the total of 5 half-lives is <10 days, there must be a minimum of 10 days between termination of the investigational drug and administration of PBI 05204). Note that prior liver-directed therapies will be permitted (i.e., chemoembolization, radioembolization), as long as target lesions in the liver have demonstrated growth after the liver-directed treatment. Any drug-related toxicity, with the exception of alopecia, should have recovered to ≤ Grade 1.
  7. If female, patient is pregnant or breast-feeding.
  8. Patient has evidence of a serious active infection (e.g., infection requiring treatment with intravenous antibiotics).
  9. Patient has known human immunodeficiency virus (HIV) or hepatitis B or C infection, as such patients may be at increased risk for toxicity due to concomitant treatment, and disease-related symptoms may preclude accurate assessment of the safety of PBI 05204.
  10. Patient has an important medical illness or abnormal laboratory finding that, in the Investigator's opinion, would increase the risk of participating in this study.
  11. Patient has a history of other malignancy treated with curative intent within the previous 5 years with the exception of adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix. Patients with previous invasive cancers are eligible if the treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease.
  12. Patient was previously exposed to PBI 05204.
  13. Patient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to PBI-05204 (i.e., cardiac glycoside compounds).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02329717

Layout table for location information
United States, Arizona
Scottsdale Healthcare Hospitals
Scottsdale, Arizona, United States, 85258
United States, Florida
Florida Hospital Tampa
Tampa, Florida, United States, 33613
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Virginia
Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
United States, Washington
Virginia Mason Medical Center
Seattle, Washington, United States, 98111
Sponsors and Collaborators
Phoenix Biotechnology, Inc
Layout table for investigator information
Principal Investigator: Jordan Berlin, MD Vanderbilt University
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Phoenix Biotechnology, Inc Identifier: NCT02329717    
Other Study ID Numbers: 2014-4350
First Posted: January 1, 2015    Key Record Dates
Last Update Posted: September 29, 2016
Last Verified: September 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type